Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Yang, Victor; Kragstrup, Tue W.; McMaster, Christopher; Reid, Pankti; Singh, Namrata; Haysen, Stine R.; Robinson, Philip C.; Liew, David F. L.

doi:10.1007/s40264-023-01333-0

Cited by 14 publications

(3 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the obvious appeal of JAK inhibitors, as an oral fast‐acting and highly effective medical therapy for several chronic inflammatory conditions, concerns regarding herpes zoster infections, venous thromboembolism, malignancy, and cardiovascular risks remain to be considered. 9 , 10 , 11 These risks are particularly relevant to older and comorbid patient populations, highlighting the need to adopt risk mitigation strategies such as vaccination against herpes zoster infection. Moreover, several of these risks may be dose related, highlighting the need to dose reduce JAK inhibitors as soon as practicable.…”

Section: Discussionmentioning

confidence: 99%

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

Hilley,

Con,

Choy

et al. 2023

JGH Open

View full text Add to dashboard Cite

Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m2. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid‐refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of “real‐world” data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid‐refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

Hilley,

Con,

Choy

et al. 2023

JGH Open

View full text Add to dashboard Cite

show abstract

“…ТОФА зарекомендовал себя эффективным препаратом для лечения ревматоидного артрита с быстрым наступлением эффекта и хорошим профилем безопасности [13]. В отношении ПсА в настоящее время идет активный набор данных об особенностях лечебного ответа у пациентов с различным фенотипом, об эффективности, безопасности, оптимальной лекарственной форме, удержании терапии при ее длительном применении [6,[14][15][16]. Так, L. Eder et al провели апостериорный анализ данных OPAL Broaden, OPAL Beyond и долгосрочного расширенного исследования OPAL Balance и заключили, что эффективность ТОФА, а также безопасность лечения и выживаемость терапии в целом не различается у пациентов мужского и женского пола [17].…”

Section: эффективность тофацитинибаunclassified

Efficacy of tofacitinib in psoriatic arthritis: literature review and case report

Gridneva,

Aronova

2023

Medicinskij sovet

View full text Add to dashboard Cite

The article presents the results of a search in the PubMed and Google Scholar databases (meta-analyses, systematic reviews, clinical trials and case studies) evaluating the treatment of PsA with tofacitinib (TOFA). The review contains the most up-to-date information about the efficacy and safety of TOFA, a drug from the group of janus kinase inhibitors (JAKi), a brief description of the mechanism of action of TOFA is given, with mention of blocked signaling intracellular pathways. The spectrum of “key” clinical manifestations of psoriatic arthritis (PsA) is described, in which the therapeutic potential of TOFA (peripheral arthritis, psoriasis, enthesitis and dactylitis) is most fully revealed. The results of the main randomized controlled trials (OPAL Broaden and OPAL Beyond), postmarketing trials, descriptive studies and clinical observations are considered, and the high efficacy of TOFA for the treatment of PsA patients who did not respond to therapy with synthetic disease-modifying drugs and/ or Tumor Necrosis Factor inhibitors (TNFi) is demonstrated. The results (and their interpretation) of studying the safety of long-term use of different doses of TOFA – 5 mg 2 times a day and 10 mg 2 times a day and retention (“survival”) are presented therapy, with an emphasis on adverse events of special interest (“large” cardiological events (MACE), oncologics, infections). The results of treatment with tofacitinib in patients with PsA according to the All-Russian register of patients are presented. The pronounced positive effect of TOFA on the parameters that are defined as “patient-reported outcome – PRO” is particularly emphasized: indicators of fatigue, self-assessment, patient’s assessment of his condition according to VAS, assessment by HAQ-DI (Health Assessment Questionnaire), SF-36 (non-specific questionnaire for quality assessment patient’s life), etc. A clinical observation is presented that demonstrates a vivid therapeutic effect on arthritis, enteritis, dactylitis, clinical signs of spondylitis, sacroiliitis, as well as the skin process in a patient with active PsA.

show abstract

“…Due to potential variations in the interpretation of regulations by different physicians, coupled with specific clinical recommendations for patient selection for JAKi use in each IMID, the implementation of regulatory guidance is of utmost importance [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Solitano,

Facheris,

Petersen

et al. 2024

Autoimmunity Reviews

View full text Add to dashboard Cite

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Cited by 14 publications

References 139 publications

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

Efficacy of tofacitinib in psoriatic arthritis: literature review and case report

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Contact Info

Product

Resources

About